NewAmsterdam Pharma (NASDAQ:NAMS) Releases Quarterly Earnings Results, Beats Estimates By $0.35 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) posted its quarterly earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.35, FiscalAI reports. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $7.54 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.

NewAmsterdam Pharma Trading Up 4.8%

NAMS traded up $0.95 during trading on Wednesday, reaching $20.86. 1,540,227 shares of the company were exchanged, compared to its average volume of 1,171,273. NewAmsterdam Pharma has a 52 week low of $19.13 and a 52 week high of $42.21. The stock has a market cap of $2.49 billion, a P/E ratio of -9.66 and a beta of 0.15. The firm has a 50 day moving average of $22.56 and a 200 day moving average of $29.71.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NAMS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Sunday. Jefferies Financial Group reissued a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, Royal Bank Of Canada reduced their price objective on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.90.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 50,246 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.03, for a total value of $1,257,657.38. Following the sale, the insider owned 69,302 shares in the company, valued at approximately $1,734,629.06. This trade represents a 42.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the completion of the sale, the director owned 8,760 shares in the company, valued at $221,803.20. The trade was a 15.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 176,846 shares of company stock worth $4,661,919 in the last ninety days. 12.74% of the stock is owned by insiders.

Key NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: The European Commission approved Ubeslo (obicetrapib alone) and Evlarco (obicetrapib with ezetimibe), marking the first regulatory approvals of obicetrapib worldwide. The approvals move the company’s products closer to commercialization in Europe. NewAmsterdam Pharma corporate update and Q3 results
• Positive Sentiment: Third-quarter adjusted loss was $0.14 per share, narrower than the $0.49 loss analysts expected. Revenue of $19.16 million also exceeded the $7.54 million consensus estimate; reports said the net loss narrowed and revenue grew. NewAmsterdam Pharma Q3 net loss narrows, revenue grows
• Positive Sentiment: Stifel reiterated that it sees the investment setup as “very compelling and significantly upside-biased,” adding supportive analyst sentiment. Stifel on NewAmsterdam Pharma
• Negative Sentiment: Despite the earnings beat, NAMS remained loss-making in the quarter. Investors will likely look for evidence that the European approvals translate into commercial uptake and revenue growth.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.